US OptionsDetailed Quotes
HUMA241220P5500
- 1.55
- 0.000.00%
15min DelayClose Dec 12 16:00 ET
0.00High0.00Low
1.55Open1.55Pre Close0 Volume7 Open Interest5.50Strike Price0.00Turnover229.52%IV3.19%PremiumDec 20, 2024Expiry Date1.42Intrinsic Value100Multiplier8DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.7662Delta0.2257Gamma2.59Leverage Ratio-0.0267Theta-0.0009Rho-1.98Eff Leverage0.0018Vega
Humacyte Stock Discussion
Sign in to post a comment
$Humacyte (HUMA.US)$ is this stock a scam?
2
$Humacyte (HUMA.US)$
🏄🏼♂️🏄🏼♂️🏄🏼♂️
🏄🏼♂️🏄🏼♂️🏄🏼♂️
$Humacyte (HUMA.US)$
🥱🥱🥱😴😴😴
🥱🥱🥱😴😴😴
1
1
$Humacyte (HUMA.US)$
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
2
2
NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
65
9
9
$Humacyte (HUMA.US)$ Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Benzinga· 3 mins ago
Benzinga· 3 mins ago
1
$Humacyte (HUMA.US)$
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
1
$Humacyte (HUMA.US)$ shd i sell this shit stock ?
2
$Humacyte (HUMA.US)$ Humacyte Presents Preclinical Results Of Small-Diameter ATEV For Coronary Artery Bypass Grafting At American Heart Association's Scientific Sessions 2024; SdATEV Was Observed To Recellularize With Host Cells And Remodel To Effectively Reduce The Initial Size Mismatch Between The SdATEV And The Animal's Native Artery
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
2
No comment yet
BFSkinner : No, it was doing well til they got their wrist slapped for cutting corners in their research
104983812 OP : so will it crawl bk feel like selling to cut losses hold for 5 months already